CureVac, Sanofi Pasteur and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency (DARPA)
Collaboration validates, diversifies and further strengthens CureVac®
Story content courtesy of CureVac GmbH and b3 Newswire, DE
The research proposal selected by DARPA involves collaboration among CureVac, Sanofi Pasteur (including Sanofi Pasteur VaxDesign Corp.) and In-Cell-Art S.A.S., a French biotech company contributing its nanoparticle technology. In this 4-year project, CureVac and the others will further advance key aspects of CureVac’s RNActive® technology platform and will evaluate several vaccine candidates in a number of relevant disease models.
Parallel to the collaboration agreements, CureVac and Sanofi Pasteur have also signed an option agreement with pre-agreed license terms for several pre-defined pathogens. “The opportunity to collaborate with a world-leading vaccine company such as Sanofi Pasteur is an exciting step as we continue to demonstrate in both the commercial and defense-related settings the broad applicability and versatility of our RNActive® technology platform, which may become game changing for the vaccine field,” adds Karl-Josef Kallen, Head of R&D at CureVac.
